http://www.newstin.com/us/ZIOPHARM_ONCOLOGY Global Social News Platform Copyright © 2006 I2S a.s. Copyright © 2006 I2S a.s. http://www.newstin.com/tag/us/74529089 NEW YORK----ZIOPHARM Oncology, Inc. announced today that it has received notice from the European Patent Office that it intends to grant a patent with claims covering certain pharmaceutical formulations of indibulin for oral... Mon, 18 Aug 2008 13:41:58 GMT http://www.newstin.com/tag/us/74529089 2008-08-18T13:41:58Z http://www.newstin.com/tag/us/72142952 News source: Business Wire ZIOPHARM Oncology, Inc. announced today the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of Leukemia, a Nature... Mon, 04 Aug 2008 12:34:38 GMT http://www.newstin.com/tag/us/72142952 2008-08-04T12:34:38Z http://www.newstin.com/tag/us/71541094 News source: Business Wire ZIOPHARM Oncology, Inc. announced today its financial results for the three and six-month periods ended June 30, 2008. The Company reported a net loss for the second quarter of 2008 of $6.5 million,... Thu, 31 Jul 2008 15:17:35 GMT http://www.newstin.com/tag/us/71541094 2008-07-31T15:17:35Z http://www.newstin.com/tag/us/71632015 of Halle, Germany, received U.S. Patent No. 7,371,404, titled "Amphoteric liposomes and their use." Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,374,752, titled "Reovirus for the Treatment of... Thu, 31 Jul 2008 20:18:53 GMT http://www.newstin.com/tag/us/71632015 2008-07-31T20:18:53Z http://www.newstin.com/tag/us/70373605 Ziopharm Oncology has reported positive data from two Phase I studies of indibulin, its novel, orally administered, synthetic tubulin targeted agent. A total of 34 patients have been treated in the two Phase I studies (Phase I... Fri, 25 Jul 2008 00:54:58 GMT http://www.newstin.com/tag/us/70373605 2008-07-25T00:54:58Z http://www.newstin.com/tag/us/70012238 MONTEREY, Calif.----ZIOPHARM Oncology, Inc. announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the American Association... Wed, 23 Jul 2008 11:32:02 GMT http://www.newstin.com/tag/us/70012238 2008-07-23T11:32:02Z http://www.newstin.com/tag/us/66070606 Griffin Securities, Inc. Updates Research Coverage on ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP) with a BUY Rating and establishes a 12-month target of $15 per share. Chrystyna Bedrij, Director of Research issued the report. Wed, 02 Jul 2008 15:56:00 GMT http://www.newstin.com/tag/us/66070606 2008-07-02T15:56:00Z http://www.newstin.com/tag/us/64393294 Posted on: Tuesday, 24 June 2008, 02:30 CDT ArQule, a biotechnology company engaged in the R&D of small-molecule cancer therapeutics, has appointed Brian Schwartz as its new chief medical officer, effective July 14, 2008. Dr... Tue, 24 Jun 2008 07:30:29 GMT http://www.newstin.com/tag/us/64393294 2008-06-24T07:30:29Z http://www.newstin.com/tag/us/63842712 Biotechnology company ArQule Inc. named Dr. Brian Schwartz its chief medical officer effective July 14, replacing Dr. Nigel Rulewski. He most recently worked as senior vice president of clinical and regulatory affairs, and... Fri, 20 Jun 2008 18:26:01 GMT http://www.newstin.com/tag/us/63842712 2008-06-20T18:26:01Z http://www.newstin.com/tag/us/63795859 ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today changes and new appointments in its clinical and regulatory groups together with the departure of Brian Schwartz, MD, Chief Medical Officer, who will be leaving the Company... Fri, 20 Jun 2008 14:00:57 GMT http://www.newstin.com/tag/us/63795859 2008-06-20T14:00:57Z